Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Rebuts Teva’s ‘Doomsday Scenario’ On Skinny-Label Generics

Originator Urges US Supreme Court To Reject Review Of Indication Carve-Out Lawsuit

Executive Summary

GSK has lodged its opposition to Teva’s bid to resurrect long-running US litigation over “skinny-label” indication carve-outs at the Supreme Court level, claiming that Teva’s warnings of a “doomsday scenario” for generics are overstated.

You may also be interested in...



Skinny-Label Saga Hangs In Balance As Supreme Court Seeks Input

As the US Supreme Court deliberates on whether to grant Teva’s petition to review its litigation with GSK over “skinny label” generics that carve out patented indications, Aziz Burgy, partner at Axinn, Veltrop & Harkrider LLP, talks to Generics Bulletin about the key issues at stake.

GSK: ‘Armageddon’ Claims Overstated For Skinny-Label Generics

In a brief opposing Teva’s call for a US appeals court to rehear controversial litigation over carved-out indications and induced infringement, GSK has insisted that previous decisions in its favor do not amount to doomsday for skinny-label generics.

Teva Coreg Damages Reinstated As AAM Bemoans ‘Antithetical’ Ruling

Teva has once again been instructed to compensate GSK with $235m in damages after a split US Court of Appeals reversed a lower court finding that Teva had not willfully induced infringement of a method-of-use patent shielding the originator’s Coreg antihypertensive.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel